Use of PET/CT Imaging With 18F-fluoroethylcholine (FEC) in the Evaluation of Patients Treated With Radiotherapy and Temozolomide Following a Diagnosis of Glioblastoma Multiforme
Inclusion Criteria
Inclusion criteria:
- Age between 18 and 70 years of age
- Histological diagnosis of GBM (grade IV astrocytoma based on the World Health
Organization [WHO] classification)
- No previous radiotherapy or chemotherapy
- No history of previous neoplasms
- Inoperable patients (tumour in place, biopsy only)
- KPS ≥ 70
- Adequate hematological, renal and hepatic function
- Absolute neutrophil count ≥ 1,500/mm3
- Platelets ≥ 100,000 per mm3
- Serum creatinine ≤ 1.5 times the upper limit of normal of the laboratory where
it is measured
- Total bilirubin ≤ 1.5 times the upper limit of normal of the laboratory where it
is measured
- Liver enzymes < 3 times the upper limit of normal of the laboratory where they
are measured
- Patients under corticosteroids must have received a stable or decreasing dose in the
14 days preceding randomization
- Consent form signed by the patients